Repligen Corporation (RGEN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Total Revenue Chart for Repligen Corporation

Repligen Corporation (RGEN) revenue for FY2025 was USD 738.3M, a 16.4% change from FY2024. Repligen Corporation's revenue grew from USD 3.6M in 1985 to USD 738.3M in 2025 (20407.1% over 40 years). Earnings per share grew from USD 0.02 in 2005 to USD 3.24 in 2022 (14151.7%). Revenue compound annual growth rate: 5-year CAGR of 15.0%, 10-year CAGR of 24.3%, 20-year CAGR of 22.4%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$9.87B
Implied Share Price
$174.86
Enterprise Value
$10.29B
Revenue (TTM)
$785.10M
EBITDA
$144.10M
Profit Margin
5.29%
Trailing P/E
260.99
Forward P/E
67.11
Price/Book (MRQ)
4.93
Price/Sales (TTM)
12.57
EV/EBITDA
53.61
EV/Revenue
11.72
Dividend Yield
—
Book Value
$37.43
Free Cash Flow (FY2025)
$93.90M
Free Cash Flow Yield
0.95%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.